Nabilone may help agitation in dementia but there is no convincing evidence that cannabinoids help cognition
A systematic review of five trials found nabilone may reduce agitation in dementia patients, but THC showed no significant benefit for agitation and no studies tested cannabinoids for cognitive decline.
Quick Facts
What This Study Found
Nabilone (1-2 mg/day) showed significant improvement in agitation in one trial. THC (1.5-4.5 mg/day) showed no significant differences from placebo for agitation in two trials. Dronabinol (5 mg/day) improved weight in one anorexia-focused trial. No studies examined cannabinoids for cognitive symptoms.
Key Numbers
5 RCTs included; nabilone 1-2 mg/day improved agitation; THC 1.5-4.5 mg/day no benefit for agitation; dronabinol 5 mg/day improved weight; 0 studies on cognitive decline; evidence rated low to very low
How They Did This
Systematic review following PRISMA guidelines, searching Medline, Embase, Cochrane, and PsycINFO. Five randomized controlled trials met inclusion criteria.
Why This Research Matters
With dementia patients and families seeking new treatment options, this review provides a clear picture: there is a thin line of evidence for nabilone in agitation but essentially no support for cannabinoids improving cognition or disease progression.
The Bigger Picture
The distinction between nabilone (synthetic, possibly effective for agitation) and THC (natural, no clear benefit) suggests that different cannabinoids may have very different utility in dementia, and lumping them together is unhelpful.
What This Study Doesn't Tell Us
Only five trials with low to very low quality evidence. Small sample sizes. Different cannabinoid preparations tested. No studies on cognitive outcomes. Short follow-up periods.
Questions This Raises
- ?Why did nabilone succeed where THC failed for agitation?
- ?Should future trials focus exclusively on nabilone for behavioral symptoms?
- ?Would CBD, which has not been tested for dementia, show different results?
Trust & Context
- Key Stat:
- Nabilone may help agitation but no cannabinoid has been shown to help dementia cognition
- Evidence Grade:
- Systematic review with low to very low quality evidence from five small trials
- Study Age:
- Published in 2021. The evidence base for cannabinoids in dementia remains extremely limited.
- Original Title:
- Effectiveness of Cannabinoids for Treatment of Dementia: A Systematic Review of Randomized Controlled Trials.
- Published In:
- Clinical gerontologist, 44(1), 16-24 (2021)
- Database ID:
- RTHC-03055
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Can cannabinoids help with dementia?
One trial found the synthetic cannabinoid nabilone may reduce agitation. However, natural THC showed no benefit for agitation, and no studies have tested any cannabinoid for cognitive decline in dementia.
Should dementia patients try cannabis?
Based on current evidence, it may be too early to recommend cannabinoids for dementia. Nabilone shows some promise for agitation specifically, but the evidence is rated low quality and more research is needed.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-03055APA
Charernboon, Thammanard; Lerthattasilp, Tiraya; Supasitthumrong, Thitipon. (2021). Effectiveness of Cannabinoids for Treatment of Dementia: A Systematic Review of Randomized Controlled Trials.. Clinical gerontologist, 44(1), 16-24. https://doi.org/10.1080/07317115.2020.1742832
MLA
Charernboon, Thammanard, et al. "Effectiveness of Cannabinoids for Treatment of Dementia: A Systematic Review of Randomized Controlled Trials.." Clinical gerontologist, 2021. https://doi.org/10.1080/07317115.2020.1742832
RethinkTHC
RethinkTHC Research Database. "Effectiveness of Cannabinoids for Treatment of Dementia: A S..." RTHC-03055. Retrieved from https://rethinkthc.com/research/charernboon-2021-effectiveness-of-cannabinoids-for
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.